前梯度蛋白2(AGR2)單克隆抗體
Monoclonal Antibody to Anterior Gradient 2 (AGR2)
GOB4; HAG2; XAG2; AG2; PDIA17; HPC8; Anterior Gradient Protein 2; Protein Disulfide Isomerase Family A,Member 17; Secreted cement gland protein XAG-2 homolog
- 編號(hào)MAC285Ra22
- 物種Rattus norvegicus (Rat，大鼠)相同的名稱，不同的物種。
- 來源單抗制備
- 宿主小鼠
- 效價(jià)(克隆號(hào))C3
- Ig亞型 IgG2a Kappa
- 純化方式蛋白A + 蛋白G親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原RPC285Ra01-前梯度蛋白2(AGR2)重組蛋白
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 濃度1mg/mL
- 且適物種Homo sapiens (Human，人)
- 應(yīng)用IHC
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見流式抗體。 - 下載英文說明書 中文說明書
- 規(guī)格20μl100μl200μl1ml10ml
- 價(jià)格¥ 734¥ 1714¥ 2448¥ 6120¥ 24480
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
DAB staining on IHC-P; Sample: Human Stomach Tissue; Primary Ab: 40μg/ml Mouse Anti-Rat AGR2 Antibody Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody (Catalog: SAA544Mu19)
DAB staining on IHC-P;
Sample: Human Colorectal cancer Tissue;
Primary Ab: 40μg/ml Mouse Anti-Rat AGR2 Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19)
DAB staining on IHC-P;
Sample: Human Stomach cancer Tissue;
Primary Ab: 40μg/ml Mouse Anti-Rat AGR2 Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19)
DAB staining on IHC-P;
Sample: Human Pancreas Tissue;
Primary Ab: 40μg/ml Mouse Anti-Rat AGR2 Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19)
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)AGR2的小鼠單克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別AGR2。
用法
Western blotting: 0.5-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPC285Ra01 | 前梯度蛋白2(AGR2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAC285Ra01 | 前梯度蛋白2(AGR2)多克隆抗體 | IHC |
| LAC285Ra71 | 前梯度蛋白2(AGR2)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| MAC285Ra22 | 前梯度蛋白2(AGR2)單克隆抗體 | IHC |
| MAC285Ra23 | 前梯度蛋白2(AGR2)單克隆抗體 | WB |
| MAC285Ra26 | 前梯度蛋白2(AGR2)單克隆抗體 | WB; IHC; ICC; IP. |
| MAC285Ra21 | 前梯度蛋白2(AGR2)單克隆抗體 | IHC |
| MAC285Ra24 | 前梯度蛋白2(AGR2)單克隆抗體 | WB; IHC; ICC; IP. |
| MAC285Ra27 | 前梯度蛋白2(AGR2)單克隆抗體 | IHC |
| MAC285Ra25 | 前梯度蛋白2(AGR2)單克隆抗體 | IHC |
| KSC285Ra01 | 前梯度蛋白2(AGR2)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | 自己動(dòng)手制作ELISA試劑盒的主要材料 |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Cancer Biomarkers | Serum AGR2 as an early diagnostic and postoperative prognostic biomarker of human lung adenocarcinoma[MetaPress: n7137r6271u54118] |
| Molecular & Cellular Proteomics | Integrated Proteomic Profiling of Cell Line Conditioned Media and Pancreatic Juice for the Identification of Pancreatic Cancer Biomarkers[PubMed: PMC3205865] |
| Prostate. | Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype[Pubmed: 22911164] |
| BMC Cancer. | Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9[Pubmed: 24007603] |
| Clinical Cancer Research | Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer[Pubmed:25239611] |
| PLoS One | AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection[PubMed: 25875093] |
| Clinical Neurology and Neurosurgery | Serum AGR2 as a useful biomarker for pituitary adenomas[S0303846717300045] |
| Oncotarget | Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2)[Pubmed:29937991] |
| Int J Oncol | Anterior gradient protein 2 is a marker of tumor aggressiveness in breast cancer and favors chemotherapy?induced senescence escape[34913074] |
| International Journal of Cancer | Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer[Pubmed:35689436] |